Eyevensys is a clinical stage, private, biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease.
EyeCET stands for the eye ciliary muscle electro-transfection technology, which uses electroporation to deliver plasmids coding for therapeutic proteins in the eye. EyeCET is safe and non-viral, and it enables the ciliary muscle cells to sustainably produce therapeutic proteins locally.
Eyevensys believes its EyeCET technology can improve short and long-term therapeutic outcomes, greatly enhancing patient compliance and significantly improve the tolerability of treatment.
Eyevensys’ lead product EYS606 is a potential new treatment for patients with non-infectious Uveitis (NIU), the 4th cause of blindness in the world.
EYS606 uses Eyevensys’ proprietary electro-transfection injection system (ETIS) to deliver a plasmid encoding for the production of an anti-TNF alpha-alpha cytokine that has been shown to play a pivotal role in mediating intraocular inflammation in NIU. EYS606 which been granted an Orphan designation by the EMA for the treatment of NIU, has received in February 2017 the regulatory clearances from the UK MHRA and the French ANSM Health Agencies to begin a Phase I/II clinical trials.
Subsequently, a multicentre clinical study has just been initiated in France and the UK.
EyeCET stands for the eye ciliary muscle electro-transfection technology, which uses electroporation to deliver plasmids coding for therapeutic proteins in the eye. EyeCET is safe and non-viral, and it enables the ciliary muscle cells to sustainably produce therapeutic proteins locally.
Eyevensys believes its EyeCET technology can improve short and long-term therapeutic outcomes, greatly enhancing patient compliance and significantly improve the tolerability of treatment.
Eyevensys’ lead product EYS606 is a potential new treatment for patients with non-infectious Uveitis (NIU), the 4th cause of blindness in the world.
EYS606 uses Eyevensys’ proprietary electro-transfection injection system (ETIS) to deliver a plasmid encoding for the production of an anti-TNF alpha-alpha cytokine that has been shown to play a pivotal role in mediating intraocular inflammation in NIU. EYS606 which been granted an Orphan designation by the EMA for the treatment of NIU, has received in February 2017 the regulatory clearances from the UK MHRA and the French ANSM Health Agencies to begin a Phase I/II clinical trials.
Subsequently, a multicentre clinical study has just been initiated in France and the UK.
Location: France, Ile-de-France, Paris
Employees: 11-50
Total raised: $52.12M
Founded date: 2008
Investors 3
Funding Rounds 3
| Date | Series | Amount | Investors |
| 04.08.2021 | Series B | $12M | - |
| 08.01.2020 | Series B | $30M | - |
| 15.09.2016 | Series A | $10.12M | - |
Mentions in press and media 10
| Date | Title | Description |
| 09.08.2021 | AbbVie hands over $20M for Alzheimer's, Parkinson's drugs; Autolus boosted by a PIM | AbbVie is paying $20 million to buy in new drug candidates from UK biotech Mission Therapeutics, which will aim to go after Alzheimer’s and Parkinson’s. Mission’s specialty is deubiquitylating enzyme (DUB) targets — following their own path... |
| 09.08.2021 | Daily funding roundup - August 9th, 2021 | Snorkel AI raised $85M; Cadence landed $41M; Canopy Servicing secured $15M Eyevensys picks up $12M Trendyol: Trendyol is a Turkey-based e-commerce platform that ranks as the largest of its kind in the country. Trendyol has raised $1.5 billi... |
| 09.08.2021 | Eyevensys Raises $12M in Series B+ Funding | Eyevensys, a Paris, France and Cambridge MA-based biotechnology company developing non-viral gene therapies for ophthalmic diseases, raised $12M in Series B+ funding. The round was led by Korea Investment Partners. The company intends to us... |
| 04.08.2021 | Eyevensys : Raises $12M in a Series B Plus Funding Round | Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announces it has raised $12M in a Series B Plus funding round. Korea Investment Partners is leading the Ser... |
| 28.08.2020 | Podcast potpourri | Dr. Rahhal is quickly becoming a prolific podcaster. In this week's roundup Firas hosts three podcasts with another impressive list of guests offering different perspectives on ophthalmic innovation. In this third OIS Retina Podcast, host ... |
| 10.01.2020 | 23andMe finds a buyer for its IL-36 bispecific in Almirall; Neurocrine, Idorsia revise epilepsy drug deal | → The first fruits of 23andMe’s efforts to generate new drugs off the insights it gained from a massive amount of genetic data are taking shape, and Almirall is signing up to ripen one of them. The Spanish dermatology drugma... |
| 08.01.2020 | Top tech startup news for today, Wednesday, January 8, 2020 – Apple, ClassPass, MedRisk, BigID, Alitheon, Roofstock | Good morning! Below are the top tech startups news for today, Wednesday, January 8, 2020. Apple’s App Store platform grossed around $50 billion in 2019, paid $155 billion to developers since 2008. Tech giant Apple reported around $50 billi... |
| 08.01.2020 | Eyevensys Raises $30M in Series B Financing | Eyevensys, a Paris, France-based clinical-stage biotechnology company developing non-viral gene therapies for retinal and other ophthalmic diseases, completed a $30m Series B financing. The round was led by Boehringer Ingelheim Venture Fund... |
| 15.09.2016 | Eyevensys Raises €9M in Series A Funding | Eyevensys, a Paris, France-based biotechnology company, raised €9m in Series A funding. The round was led by Pontifax Venture Capital. In conjunction with the closing of the round, Mr. Ohad Hammer from Pontifax joined the Eyevensys Board. T... |
| 11.04.2013 | Eyevensys Raises Funds from Boehringer Ingelheim Venture Fund | Eyevensys, a Paris, France-developer of a new non-viral gene therapy process to treat ocular illnesses, announces an equity investment of undisclosed amount by Boehringer Ingelheim Venture Fund. In conjunction with the funding, Dr Michel Pa... |